

## Refine Search

---

### Search Results -

Terms	Documents
L7 and minimal	3

---

**Database:** US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

**Search:**  

---

### Search History

---

**DATE:** Saturday, November 10, 2007    [Purge Queries](#)    [Printable Copy](#)    [Create Case](#)

<u>Set</u> <u>Name</u> <u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
side by side		
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<u>L12</u> L7 and minimal	3	<u>L12</u>
<u>L11</u> L7 and (brain or neuron\$ or neural\$)	5	<u>L11</u>
<u>L10</u> L7 and IRES	5	<u>L10</u>
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<u>L9</u> L7 and baron	3	<u>L9</u>
<u>L8</u> l7 and CMV	5	<u>L8</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<u>L7</u> (bi-direction\$ or bidirection\$) near10 promoter\$ near25 (retrovir\$ or lentivir\$) and transgenic	5	<u>L7</u>
<u>L6</u> (bi-direction\$ or bidirection\$) near10 promoter\$ and transgenic and (retrovir\$ or lentivir\$)	167	<u>L6</u>
<u>L5</u> L1 and (brain or neuron\$ or neura\$)	2	<u>L5</u>
<u>L4</u> L1 and IRES	0	<u>L4</u>

<u>L3</u>	L1 and ex	0	<u>L3</u>
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L2</u>	L1 and (retrovir\$ or lentivir\$)	0	<u>L2</u>
<u>L1</u>	7265259 [pn]	2	<u>L1</u>

END OF SEARCH HISTORY

 PALM INTRANETDay : Saturday  
Date: 11/10/2007

Time: 17:28:33

## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.

Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name****First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

 PALM INTRANETDay : Saturday  
Date: 11/10/2007

Time: 17:28:33

## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name
amendola	mario

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

 PALM INTRANETDay : Saturday  
Date: 11/10/2007

Time: 17:28:33

## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.

Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name****First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

Set	Items	Description
? set hi ;set hi		
HIGHLIGHT	set on as ''	
HIGHLIGHT	set on as ''	
? begin	5,6,55,154,155,156,312,399,biotech,biosci,biosis	

```
Set Items Description
--- -----
? s (bidirection? or bi-direction?) (5n) promoter?
    84509 BIDIRECTION?
    1963 BI-DIRECTION?
    1419663 PROMOTER?
S1    3645 (BIDIRECTION? OR BI-DIRECTION?) (5N) PROMOTER?
? s s1 and (CMV or cytomegalovir?) (5n) minimal
    3645 S1
    116925 CMV
    238719 CYTOMEGALOVIR?
    1114888 MINIMAL
    783 (CMV OR CYTOMEGALOVIR?) (5N)MINIMAL
S2    12 S1 AND (CMV OR CYTOMEGALOVIR?) (5N) MINIMAL
? rd s2
```

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.  
S3 5 RD S2 (unique items)

? d s3/3/1-5  
Display 3/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

18572346 BIOSIS NO.: 200510266846  
An establishment of a system for conditional overexpression of genes in megakaryocytes and platelets in vivo  
AUTHOR: Nguyen Hao G (Reprint); Yu Guangao; Makitalo Maria; Jones Matthew; Ravid Katya  
AUTHOR ADDRESS: Boston Univ, Sch Med, Boston, MA 02215 USA\*\*USA  
JOURNAL: Blood 104 (11, Part 2): p135B NOV 16 2004 2004  
CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004;  
20041204  
SPONSOR: Amer Soc Hematol  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

- end of record -

?  
Display 3/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2007 The Thomson Corporation. All rts. reserv.

18489268 BIOSIS NO.: 200510183768  
Conditional overexpression of transgenes in megakaryocytes and platelets in vivo  
AUTHOR: Nguyen Hao G; Yu Guangyao; Makitalo Maria; Yang Dan; Xie Hou-Xiang; Jones Matthew R; Ravid Katya (Reprint)  
AUTHOR ADDRESS: Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Dept Biochem, 715 Albany St, K225, Boston, MA 02118 USA\*\*USA  
AUTHOR E-MAIL ADDRESS: ravid@biochem.bumc.bu.edu  
JOURNAL: Blood 106 (5): p1559-1564 SEP 1 2005 2005  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

- end of record -

?

Display 3/3/3 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

141406766 CA: 141(25)406766e PATENT  
Bicistronic lentiviral vectors carrying synthetic bi-directional  
promoters for gene therapy in human  
INVENTOR(AUTHOR): Naldini, Luigi; Amendola, Mario; Vigna, Elisa  
LOCATION: Italy  
ASSIGNEE: Fondazione Centro San Raffaele del Monte Tabor  
PATENT: PCT International ; WO 200494642 A2 DATE: 20041104  
APPLICATION: WO 2004IT227 (20040421) \*US PV465080 (20030424)  
PAGES: 54 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-015/86A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;

-more-

?  
Display 3/3/3 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;  
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;  
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;  
SN; TD; TG

- end of record -

?  
Display 3/3/4 (Item 1 from file: 24)  
DIALOG(R)File 24:CSA Life Sciences Abstracts  
(c) 2007 CSA. All rts. reserv.

0001541563 IP ACCESSION NO: 3807151  
Co-regulation of two gene activities by tetracycline via a  
bidirectional promoter

Baron, U; Freundlieb, S; Gossen, M; Bujard, H\*  
Zent. Mol. Biol. Univ. Heidelberg (ZMBH), Im Neuenheimer Feld 282, 69120  
Heidelberg, FRG

Nucleic Acids Research, v 23, n 17, p 3605-3606, 1995  
ADDL. SOURCE INFO: Nucleic Acids Research [NUCLEIC ACIDS RES.], vol. 23,  
no. 17, pp. 3605-3606, 1995  
PUBLICATION DATE: 1995

DOCUMENT TYPE: Journal Article  
RECORD TYPE: Abstract  
LANGUAGE: English

-more-

?  
Display 3/3/4 (Item 1 from file: 24)  
DIALOG(R)File 24:CSA Life Sciences Abstracts  
(c) 2007 CSA. All rts. reserv.  
ISSN: 0305-1048  
FILE SEGMENT: Nucleic Acids Abstracts

- end of record -

?

Display 3/3/5 (Item 1 from file: 144)  
DIALOG(R)File 144:Pascal  
(c) 2007 INIST/CNRS. All rts. reserv.

17450419 PASCAL No.: 06-0032787  
Conditional overexpression of transgenes in megakaryocytes and platelets  
in vivo. Commentary  
NGUYEN Hao G; GUANGYAO YU; MAKITALO Maria; DAN YANG; XIE Hou-Xiang; JONES  
Matthew R; RAVID Katya; WARE Jerry comment  
Department of Biochemistry, Whitaker Cardiovascular Institute, Boston  
University School of Medicine, Boston, MA, United States; UNIVERSITY OF  
ARKANSAS FOR MEDICAL SCIENCES, United States  
Journal: Blood, 2005, 106 (5) 1511-1512, 1559-1564 (8 p.)  
Language: English

Copyright (c) 2006 INIST-CNRS. All rights reserved.

- end of record -

?

? s s1 and CMV and (phosphoglycerate or ubiquitin) and minimal  
3645 S1  
116925 CMV  
29150 PHOSPHOGLYCERATE  
156625 UBIQUITIN  
1114888 MINIMAL  
S4 1 S1 AND CMV AND (PHOSPHOGLYCERATE OR UBIQUITIN) AND  
MINIMAL

? d s4/9/1

Display 4/9/1 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2007 The Thomson Corp. All rts. reserv.

0410068 DBR Accession No.: 2006-23564 PATENT  
New nucleic acid molecule encoding recombinant seven transmembrane  
G-protein associated receptor, useful for imaging or treating cancer -  
involving vector-mediated gene transfer and expression in host cell for  
cancer and leukemia therapy and gene therapy  
AUTHOR: KUNDRA V; FANG B; JI L X; YANG D  
PATENT ASSIGNEE: UNIV TEXAS SYSTEM 2006  
PATENT NUMBER: WO 200699019 PATENT DATE: 20060921 WPI ACCESSION NO.:  
2006-648989 (200667)  
PRIORITY APPLIC. NO.: US 659844 APPLIC. DATE: 20050309  
NATIONAL APPLIC. NO.: WO 2006US8374 APPLIC. DATE: 20060309  
LANGUAGE: English  
ABSTRACT: DERWENT ABSTRACT: NOVELTY - A nucleic acid molecule comprising a  
coding region encoding a recombinant seven transmembrane G-protein  
associated receptor (GPCR) amino acid sequence, the coding region  
operatively linked to a tissue-selective promoter sequence, is new.

-more-

?

Display 4/9/1 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2007 The Thomson Corp. All rts. reserv.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method of  
imaging or treating cells in a subject. BIOTECHNOLOGY - Preferred  
Nucleic Acid: The recombinant GPCR has a C-terminal deletion, has an  
altered internalization, is defective in intracellular signaling, or  
their combination. The GPCR is an acetylcholine receptor: M1, M2, M3,  
M4, or M5; adenosine receptor: A1; A2A; A2B; or A3; adrenoceptors:  
alpha1A, alpha1B, alpha1D, alpha2A, alpha2B, alpha2C beta1, beta2, or  
beta3; angiotensin receptors: AT1, or AT2; bombesin receptors: BB1,  
BB2, or BB3; bradykinin receptors: B1, B2, calcitonin, Aininlin, CGRP,

or adrenomedullin receptors; cannabinoid receptors: CB1, or CB2; chemokine receptors: CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CX3CR1, or XCR1; chemotactic receptors: C3a, C5a, or fMLP; cholecystokinin and gastrin receptors: CCK1, or CCK2; corticotropin-releasing factor receptors: CRF1, or CRF2; dopamine receptors: D1, D2, D3, D4, or D5; endothelin receptors: ET(A) or ET(B); galanin receptors: GAL1, GAL2, or GAL3; glutamate receptors: mgl1, mgl2, mgl3, mgl4, mgl5, mgl6o, mgl7, or

-more-

?

Display 4/9/1 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.

mgl8; glycoprotein hormone receptors: FSH, LSH, or TSH; histamine receptors: H1, H2, H3, or H4; 5-HT receptors: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1B, 5-HT1F, 5HT2A, 5-HT2F, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A, 5-HT5B, 5-HT6, or 5-HT7; leukotriene receptors: BLT, CysLT1, or CysLT2; lysophospholipid receptors: edg1, edg2, edg3, or edg4; melanocortin receptors: MC1; MC2; MC3; MC4, or MC5; melatonin receptors: MT1, MT2, or MT3; neuropeptide Y receptors: Y1, Y2, Y4, Y5, or Y6; neurotension receptors: NTS1, or NTS2; opioids: DOP, KOP, MOP, or NOP; P2Y receptors: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, or P2Y12; peroxisome proliferators: PPAR-alpha, PPAR-beta, or PPAR-gamma; prostanoid receptors: DP, FP, IP, TP, EP1, EP2, EP3, or EP4; protease-activated receptors: PAR1, PAR2, PAR3, or PAR4; Somatostatin receptors: SSTR1, SSTR2, SSTR2A, SSTR3, SSTR4, or SSTR5; tachyldnin receptors: NK1, NK2, or NK3; thyrotropin-releasing hormone receptors: TRH1, or TRH2; urotensin-II receptor; vasoactivate intestinal peptide or pituitary adenylate cyclase activating peptide receptors: VPAC1, VPAC2, or PAC1; or vasopressin or oxytocin receptors: V1a, V1b, V2, or OT. The GPCR is

-more-

?

Display 4/9/1 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.

a somatostatin receptor, where the somatostatin receptor is a somatostatin receptor type 2A (SSTR2A), where the SSTR2A is signaling defective, has altered internalization, or their combination, where the SSTR2A is truncated, and where the SSTR2A is truncated carboxy terminal to amino acid 314. The promoter sequence is a telomerase promoter, a human telomerase RNA (hTR) promoter, human telomerase reverse transcriptase promoter (hTERT) promoter, hTR operatively coupled to an amplification mechanism, or hTERT operatively coupled to an amplification mechanism. The tissue-selective promoter or amplified tissue specific promoter is active in normal and/or diseased heart, lung, esophagus, muscle, intestine, breast, prostate, stomach, bladder, liver, spleen, pancreas, kidney, neurons, myocytes, leukocytes, immortalized cells, neoplastic cells, tumor cells, cancer cells, duodenum, jejunum, ileum, cecum, colon, rectum, salivary glands, gall bladder, urinary bladder, trachea, larynx, pharynx, aorta, arteries, capillaries, veins, thymus, lymph nodes, bone marrow, pituitary gland, thyroid gland, parathyroid glands, adrenal glands, brain, cerebrum,

-more-

?

Display 4/9/1 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.

cerebellum, medulla, pons, spinal cord, nerves, skeletal muscle, smooth muscle, bone, testes, epidymidis, prostate, seminal vesicles, penis, ovaries, uterus, mammary glands, vagina, skin, eyes, optic nerve, a promoter active in tissues derived from the same embryonic origin or

one or more tissues effected by the same or similar disease, where the tissue selective promoter is active in a neoplastic cell, a tumor, or a cancer cell, e.g. a breast cancer cell, a lung cancer cell, a prostate cancer cell, an ovarian cancer cell, a brain cancer cell, a liver cancer cell, a cervical cancer cell, a colon cancer cell, a renal cancer cell, a skin cancer cell, a head and neck cancer cell, a bone cancer cell, an esophageal cancer cell, a bladder cancer cell, a uterine cancer cell, a lymphatic cancer cell, a stomach cancer cell, a pancreatic cancer cell, a testicular cancer cell, a lymphoma cell, or a leukemic cell. The promoter sequence is an hTERT promoter sequence, hTERT promoter sequence, CEA promoter sequence, a PSA promoter sequence, a probasin promoter sequence, a ARR2PB promoter sequence, AFP promoter sequence, MUC-1, MUC-4, mucin-like glycoprotein, C-erbB2/neu oncogene,

-more-

?

Display 4/9/1 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.

Cyclooxygenase, E2F transcription factor 1, tyrosinase related protein, tyrosinase, or survivin, Tcf1-alpha, Ras, Raf, cyclin E, Cdc25A, HKII, KRT19, TFF1, SEL1L, or an CEL. The promoter sequence is an hTERT promoter sequence that is functional in a cancer cell. The promoter sequence is an immunoglobulin heavy chain promoter sequence, an immunoglobulin light chain promoter sequence, a T-cell receptor promoter sequence, an HLA DQ a promoter sequence, an HLA DQ beta promoter sequence, a beta-interferon promoter sequence, an interleukin-2 promoter sequence, an interleukin-2 receptor promoter sequence, an MHC Class II 5 promoter sequence, an MHC Class II HLA-Dra promoter sequence, a beta-actin promoter sequence, a muscle creatine kinase (MCK) promoter sequence, a prealbumin (transthyretin) promoter sequence, an elastase I promoter sequence, a metallothionein (MTII) promoter sequence, a collagenase promoter sequence, an albumin promoter sequence, an alpha-fetoprotein promoter sequence, a gamma-globin promoter sequence, a beta-globin promoter sequence, a c-fos promoter sequence, a c-HA-ras promoter sequence, an insulin promoter sequence, a

-more-

?

Display 4/9/1 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.

neural cell adhesion molecule (NCAM) promoter sequence, an alpha-1-antitrypsin promoter sequence, an H2B (TH2B) histone promoter sequence, a type I collagen promoter sequence, a GRP94 promoter sequence, a GRP78 promoter sequence, an other glucose-regulated protein promoter sequence, a growth hormone promoter sequence, a human serum amyloid A (SAA) promoter sequence, a troponin I (TN I) promoter sequence, a platelet-derived growth factor (PDGF) promoter sequence, a Duchenne Muscular Dystrophy promoter sequence, an SV40 promoter sequence, a polyoma promoter sequence, a retrovirus promoter sequence, a papilloma virus promoter sequence, a Hepatitis B virus promoter sequence, a Human Immunodeficiency Virus promoter sequence, a Cytomegalovirus promoter sequence, a Gibbon Ape Leukemia Virus promoter sequence, a human LIMK2 gene promoter sequence, a somatostatin receptor promoter sequence, a murine epididymal retinoic acid-binding gene promoter sequence, a human CD4 promoter sequence, a mouse alpha2 (XI) collagen promoter sequence, a D1A dopamine receptor promoter sequence, an insulin-like growth factor II promoter sequence, human platelet

-more-

?

Display 4/9/1 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.

endothelial cell adhesion molecule-1 promoter sequence, a human alpha-lactalbumin promoter sequence, a 7SL promoter sequence, a human Y promoter sequence, a human MRP-7-2 promoter sequence, a 5S ribosomal promoter sequence, alpha fetoprotein, monocyte receptor for bacterial LPS, leukosialin, Sialophorin, leukocyte common antigen, Macrosialin or human analog of macrosialin, Desmin, Elastase, Elastase I, Endoglin, fibronectin, vascular endothelial growth factor (VEGF) receptors, glial fibrillary acidic protein, intercellular adhesion molecule 2, interferon beta, myoglobin, osteocalcin 2, prostate specific antigen, prostate specific membrane antigen, surfactant protein B, Synapsin, tyrosinase related protein, tyrosinase, or a functional hybrid, functional portion, or a combination of any of tissue/disease /lineage specific promoter sequences. The tissue-selective promoter sequence is operatively coupled to a core promoter sequence, where the core promoter sequence is derived from a constitutive promoter such as ubiquitin promoter, an actin promoter, an elongation factor 1 alpha, an early growth factor response 1, an eukaryotic initiation

-more-

?

Display 4/9/1 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.

factor 4A1, a ferritin heavy chain, a ferritin light chain, a glyceraldehyde 3-phosphate dehydrogenase, a glucose-regulated protein 78, a glucose-regulated protein 94, a heat shock protein 70, a heat shock protein 90, a beta-kinesin, a phosphoglycerate kinase, an ubiquitin B, a beta-actin or a minimal viral promoter sequence. The \*\*\*minimal\*\*\* viral promoter sequence is a RNA virus promoter, DNA virus promoter, adenoviral promoter sequence, a baculoviral promoter sequence, a CMV promoter sequence, a parvovirus promoter sequence, a herpesvirus promoter sequence, a poxvirus promoter sequence, an adeno-associated virus promoter sequence, a semiwild forest virus promoter sequence, an SV40 promoter sequence, a vaccinia virus promoter sequence, a lentivirus promoter, or a retrovirus promoter sequence. The \*\*\*minimal\*\*\* viral promoter sequence is a mini-CMV promoter sequence, where the tissue selective promoter is the hTERT promoter, and where the hTERT promoter is operatively coupled to a first reporter. The nucleic acid further comprises a second coding sequence where the second coding sequence

-more-

?

Display 4/9/1 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.

encodes a therapeutic, a selectable marker, a recombinant transactivator, or a second imaging gene (reporter). The nucleic acid comprises a first reporter is SSTR2 and a second reporter that is green fluorescent protein (GFP). The nucleic acid further comprises a second coding sequence operatively coupled to a second tissue-selective promoter sequence, or an amplified tissue specific promoter or a non-selective promoter such as a \*\*\*CMV\*\*\* promoter. The second coding sequence encodes a therapeutic, a selectable marker, a recombinant transactivator, or a second imaging gene (reporter), where the therapeutic is a tumor suppressor, an inducer apoptosis, an enzyme, a structural protein, a receptor, an antibody, an antibody fragment, a siRNA, a hormone, a paracrine factor, or an immunostimulant, and where the tumor suppressor is FUS1. The selectable marker is a drug selection marker, an enzyme, a structural protein, a receptor, a paracrine factor, an immunologic marker, or a fluorescent protein. The nucleic acid further comprises a second coding sequence, where the second coding sequence and the nucleic acid encoding the reporter are

-more-

? Display 4/9/1 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.  
(c) 2007 The Thomson Corp. All rts. reserv.  
operatively linked. The nucleic acid further comprises a second coding sequence, where the second coding sequence and the nucleic acid encoding the recombinant GPCR amino acid sequence are operatively coupled to a \*\*\*bidirectional\*\*\* \*\*\*promoter\*\*\* . The nucleic acid further comprises a second coding sequence, where the second coding sequence and the nucleic acid encoding the recombinant seven transmembrane G-protein associated receptor amino acid sequence are separated by an IRES. The nucleic acid further comprises a protein tag fused to the N-terminal end or C-terminal end of the GPCR amino acid sequence, where the protein tag has enzymatic activity, and where the protein tag is hemagglutinin A, beta-galactosidase, thymidine kinase, transferin, myc-tag, VP16, (His)e-tag, FLAG, or chloramphenicol acetyl transferase. A nucleic acid comprises a nucleic acid sequence encoding a reporter that is detectable in a subject by non-invasive methods operatively coupled to a promoter sequence that binds a recombinant transactivator. The recombinant transactivator is Gal4VP16. The nucleic acid sequence further comprises a third coding sequence operatively

-more-

? s s1 and IRES  
3645 S1  
15888 IRES  
S5 6 S1 AND IRES

? d s5/3/1-6  
Display 5/3/1 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

143280128 CA: 143(16)280128u JOURNAL  
Construction and characterization of multiple human colon cancer cell lines for inducibly regulated gene expression  
AUTHOR(S): Welman, Arkadiusz; Cawthorne, Christopher; Barraclough, Jane; Smith, Nigel; Griffiths, Gareth J.; Cowen, Rachel L.; Williams, Judith C.; Stratford, Ian J.; Dive, Caroline  
LOCATION: Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Cancer Research UK, Manchester, UK, M20 4BX  
JOURNAL: J. Cell. Biochem. (Journal of Cellular Biochemistry) DATE: 2005  
VOLUME: 94 NUMBER: 6 PAGES: 1148-1162 CODEN: JCEBD5 ISSN: 0730-2312  
LANGUAGE: English PUBLISHER: Wiley-Liss, Inc.

- end of record -

? Display 5/3/2 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

142255452 CA: 142(14)255452s JOURNAL  
Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters  
AUTHOR(S): Amendola, Mario; Venneri, Mary Anna; Biffi, Alessandra; Vigna, Elisa; Naldini, Luigi  
LOCATION: San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), San Raffaele Scientific Institute, 20132, Milan, Italy  
JOURNAL: Nat. Biotechnol. (Nature Biotechnology) DATE: 2005 VOLUME: 23  
NUMBER: 1 PAGES: 108-116 CODEN: NABIF9 ISSN: 1087-0156 LANGUAGE:  
English PUBLISHER: Nature Publishing Group

- end of record -

?

Display 5/3/3 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

141406766 CA: 141(25)406766e PATENT  
Bicistronic lentiviral vectors carrying synthetic bi-directional  
promoters for gene therapy in human  
INVENTOR(AUTHOR): Naldini, Luigi; Amendola, Mario; Vigna, Elisa  
LOCATION: Italy  
ASSIGNEE: Fondazione Centro San Raffaele del Monte Tabor  
PATENT: PCT International ; WO 200494642 A2 DATE: 20041104  
APPLICATION: WO 2004IT227 (20040421) \*US PV465080 (20030424)  
PAGES: 54 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:

CLASS: C12N-015/86A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;

-more-

?

Display 5/3/3 (Item 3 from file: 399).  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;  
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;  
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;  
SN; TD; TG

- end of record -

?

Display 5/3/4 (Item 4 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

138132167 CA: 138(10)132167n PATENT  
Retrovirus vector for reversible gene integration into mammalian cells  
for gene therapy  
INVENTOR(AUTHOR): Itoh, Akira; Hanazono, Yutaka; Ozawa, Keiya  
LOCATION: Japan,  
PATENT: U.S. Pat. Appl. Publ. ; US 20030022375 A1 DATE: 20030130  
APPLICATION: US 188075 (20020703) \*JP 2001205236 (20010705)  
PAGES: 21 pp. CODEN: USXXCO LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 435455000; C12N-015/85A; C12N-005/06B

- end of record -

?

Display 5/3/5 (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2007 The Thomson Corp. All rts. reserv.

14547360 Genuine Article#: 984NP Number References: 25  
Title: A series of bidirectional tetracycline-inducible  
promoters provides coordinated protein expression  
Author(s): Sammarco MC; Grabczyk E (REPRINT)  
Corporate Source: Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New  
Orleans//LA/70112 (REPRINT); Louisiana State Univ, Hlth Sci Ctr, Dept  
Genet, New Orleans//LA/70112; Louisiana State Univ, Hlth Sci Ctr, Dept  
Pathol, New Orleans//LA/70112(egrabc@lsuhsc.edu)

Journal: ANALYTICAL BIOCHEMISTRY, 2005, V346, N2 (NOV 15), P210-216  
ISSN: 0003-2697 Publication date: 20051115  
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN  
DIEGO, CA 92101-4495 USA  
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

- end of record -

?  
Display 5/3/6 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2007 Elsevier B.V. All rts. reserv.

12156538 EMBASE No: 2003266158  
Development of Nurrl stable cell lines for the identification of  
downstream targets  
Luo Y.; Henricksen L.A.; Maguire-Zeiss K.A.; Federoff H.J.  
Dr. H.J. Federoff, University of Rochester Sch. of Medicine, 601 Elmwood Ave.,  
Rochester, NY 14642 United States  
AUTHOR EMAIL: howard.federoff@urmc.rochester.edu  
Annals of the New York Academy of Sciences ( ANN. NEW YORK ACAD. SCI. ) ( United States) 2003, 991/- (354-358)  
CODEN: ANYAA ISSN: 0077-8923  
DOCUMENT TYPE: Journal ; Conference Paper  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 1

- end of record -

? s s1 and (retrovir? or lentivir?) (5n) vector?  
3645 S1  
717574 RETROVIR?  
114313 LENTIVIR?  
2379630 VECTOR?  
85840 (RETROVIR? OR LENTIVIR?) (5N)VECTOR?  
S6 29 S1 AND (RETROVIR? OR LENTIVIR?) (5N) VECTOR?  
? s s6 and minimal  
29 S6  
1114888 MINIMAL  
S7 2 S6 AND MINIMAL

? d s7/3/1-2  
Display 7/3/1 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2007 American Chemical Society. All rts. reserv.

141406766 CA: 141(25)406766e PATENT  
Bicistronic lentiviral vectors carrying synthetic bi-directional  
promoters for gene therapy in human  
INVENTOR(AUTHOR): Naldini, Luigi; Amendola, Mario; Vigna, Elisa  
LOCATION: Italy  
ASSIGNEE: Fondazione Centro San Raffaele del Monte Tabor  
PATENT: PCT International ; WO 200494642 A2 DATE: 20041104  
APPLICATION: WO 2004IT227 (20040421) \*US PV465080 (20030424)  
PAGES: 54 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-015/86A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;

-more-

?  
Display 7/3/1 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;  
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;  
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;  
SN; TD; TG

- end of record -

?

Display 7/3/2 (Item 1 from file: 357)  
DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.

0368894 DBR Accession Number: 2005-14600 PATENT  
New bidirectional promoter comprises control elements for  
transcription of short RNA sequences, useful for expressing short RNA  
sequences from a single promoter - method of virus infection gene  
therapy involving the use of RNA interference for virus genome gene  
expression suppression

AUTHOR: LOU K

PATENT ASSIGNEE: WELGEN INC; FRICK G P; DU L 2005

PATENT NUMBER: WO 200535718 PATENT DATE: 20050421 WPI ACCESSION NO.:  
2005-296272 (200530)

PRIORITY APPLIC. NO.: US 508821 APPLIC. DATE: 20041002

NATIONAL APPLIC. NO.: WO 2004US32158 APPLIC. DATE: 20041002

LANGUAGE: English

- end of record -

? e au=naldini, luigi

Ref	Items	Index-term
E1	7	AU=NALDINI, L*
E2	18	AU=NALDINI, LUCIANA
E3	145	*AU=NALDINI, LUIGI
E4	1	AU=NALDINI, LUIGI T
E5	4	AU=NALDINI, M.
E6	2	AU=NALDINI, N.
E7	1	AU=NALDINI, ROSELLA
E8	5	AU=NALDINI, S.
E9	1	AU=NALDINILONGO B
E10	2	AU=NALDJIAN S
E11	2	AU=NALDJIAN SANTIAGO
E12	2	AU=NALDMANN, H.

Enter P or PAGE for more

? e au=naldini luigi

Ref	Items	Index-term
E1	4	AU=NALDINI LONGO, B.
E2	2	AU=NALDINI LUCIANA
E3	313	*AU=NALDINI LUIGI
E4	3	AU=NALDINI M
E5	2	AU=NALDINI MARCO
E6	2	AU=NALDINI R
E7	1	AU=NALDINI S
E8	5	AU=NALDINI S.
E9	13	AU=NALDINI, A
E10	56	AU=NALDINI, A.
E11	113	AU=NALDINI, ANTONELLA
E12	1	AU=NALDINI, B

Enter P or PAGE for more

? e au=amendola, mario

Ref	Items	Index-term
E1	7	*AU=AMENDOLA, MARIO
E2	1	AU=AMENDOLA, MC
E3	3	AU=AMENDOLA, MICHAEL
E4	1	AU=AMENDOLA, MP
E5	2	AU=AMENDOLA, N.
E6	2	AU=AMENDOLA, P
E7	9	AU=AMENDOLA, PAOLA
E8	1	AU=AMENDOLA, PLINIO
E9	8	AU=AMENDOLA, R
E10	20	AU=AMENDOLA, R.
E11	1	AU=AMENDOLA, R. C.
E12	1	AU=AMENDOLA, R. D.

Enter P or PAGE for more

? e au=amendola mario

Ref	Items	Index-term
E1	7	*AU=AMENDOLA MARIO
E2	4	AU=AMENDOLA MARY GRACE
E3	1	AU=AMENDOLA MASSIOTTI, R.
E4	3	AU=AMENDOLA MC
E5	1	AU=AMENDOLA ME
E6	1	AU=AMENDOLA MG
E7	5	AU=AMENDOLA MICHAEL
E8	1	AU=AMENDOLA MP
E9	6	AU=AMENDOLA N
E10	8	AU=AMENDOLA N.
E11	12	AU=AMENDOLA NED
E12	1	AU=AMENDOLA O

Enter P or PAGE for more

? e au=vigna, elisa

Ref	Items	Index-term
E1	12	AU=VIGNA, E
E2	14	AU=VIGNA, E.
E3	28	*AU=VIGNA, ELISA
E4	8	AU=VIGNA, ENRICO
E5	2	AU=VIGNA, ERNESTO
E6	8	AU=VIGNA, F.
E7	1	AU=VIGNA, F.E.
E8	113	AU=VIGNA, G.
E9	14	AU=VIGNA, G. B.
E10	1	AU=VIGNA, G. L.
E11	1	AU=VIGNA, G.B.
E12	1	AU=VIGNA, GERALD S.

Enter P or PAGE for more

? e au=vigna elisa

Ref	Items	Index-term
E1	123	AU=VIGNA E
E2	48	AU=VIGNA E.
E3	28	*AU=VIGNA ELISA
E4	21	AU=VIGNA ERNESTO
E5	9	AU=VIGNA F
E6	4	AU=VIGNA F.
E7	5	AU=VIGNA F.E.
E8	1	AU=VIGNA FE
E9	1	AU=VIGNA FILHO E D
E10	1	AU=VIGNA FILHO, E.
E11	11	AU=VIGNA FRANCO
E12	4	AU=VIGNA FRANCO E

Enter P or PAGE for more  
? s el

S8 123 AU='VIGNA E'

? s s8 and bidirection?

123 S8

84509 BIDIRECTION?

S9 2 S8 AND BIDIRECTION?

? d s9/3/1-2

Display 9/3/1 (Item 1 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

(c) 2007 The Thomson Corp. All rts. reserv.

13504899 Genuine Article#: 885ZK No. References: 32

Title: Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters

Author(s): Amendola M; Venneri MA; Biffi A; Vigna E; Naldini L  
(REPRINT)

Corporate Source: San Raffaele Telethon Inst Gene Therapy HSR TIGET,Via Olgettina 58/I-20132 Milan//Italy/ (REPRINT); San Raffaele Telethon Inst Gene Therapy HSR TIGET,I-20132 Milan//Italy/; Vita Salute San Raffaele Univ, San Raffaele Sci Inst,I-20132 Milan//Italy/; Univ Turin,Sch Med, Inst Canc Res & Treatment,I-10060 Turin//Italy/(naldini.luigi@hsr.it)

Journal: NATURE BIOTECHNOLOGY, 2005, V23, N1 (JAN), P108-116

ISSN: 1087-0156 Publication date: 20050100

Publisher: NATURE PUBLISHING GROUP, 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

- end of record -

?

Display 9/3/2 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rts. reserv.

0360794 DBR Accession No.: 2005-06498

Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters - gene transfer and tissue-specific gene expression using a lenti virus expression vector useful for a gene therapy application

AUTHOR: AMENDOLA M; VENNERI MA; BIFFI A; VIGNA E; NALDINI L

CORPORATE AFFILIATE: San Raffaele Telethon Inst Gene Therapy HSR TIGET  
Vita Salute San Raffaele Univ; Univ Turin

CORPORATE SOURCE: Naldini L, San Raffaele Telethon Inst Gene Therapy HSR TIGET, Via Olgettina 58, I-20132 Milan, Italy

JOURNAL: NATURE BIOTECHNOLOGY (23, 1, 108-116) 2005

ISSN: 1087-0156

LANGUAGE: English

- end of record -

?